Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

Charles Eby, JA Johnson, Elena Deych, +15

Clinical Pharmacology & Therapeutics

CYP4F2 genetic variant alters required warfarin dose

Michael D. Caldwell, Tarif Awad, Julie A. Johnson, +16

Blood

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin

Charles Eby, Paul E. Milligan, Gerald A. Banet, +3

Thrombosis and Haemostasis

Genetic EpidemiologyHuman PolymorphismPharmacotherapyMaintenance DoseWarfarin Dose +20

Venous Thromboembolic Disease

Michael B. Streiff, Paula Bockenstedt, Spero R. Cataland, +19

Journal of the National Comprehensive Cancer Network

Risk EvaluationPathologyPharmacotherapyThrombosisVenous Thrombosis +17

Cancer-Associated Venous Thromboembolic Disease, Version 1.2015

Michael B. Streiff, Bjorn Holmstrom, Aneel A. Ashrani, +26

Journal of the National Comprehensive Cancer Network

Version 1.2015PathologyEffective ProphylaxisPharmacotherapyThrombosis +16

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype

Deepak Voora, Charles Eby, Mark W. Linder, +8

Thrombosis and Haemostasis

Genetic-based dosing in orthopedic patients beginning warfarin therapy

Eric A. Millican, Petra Lenzini, Paul E. Milligan, +11

Blood

Pancytopenia after Removal of Copper from Total Parenteral Nutrition

M. Patricia Fuhrman, Virginia M. Herrmann, Patricia Masidonski, +1

Journal of Parenteral and Enteral Nutrition

Venous Thromboembolic Disease

Michael B. Streiff, Paula Bockenstedt, Spero R. Cataland, +20

Journal of the National Comprehensive Cancer Network

Risk EvaluationPathologyPharmacotherapyThrombosisVenous Thrombosis +17

Performance of Commercial Platforms for Rapid Genotyping of Polymorphisms Affecting Warfarin Dose

Cristi R. King, Rhonda Porche-Sorbet, Brian F. Gage, +4

American Journal of Clinical Pathology